Thermo Fisher Scientific Inc. (TMO) Shares Bought by Eqis Capital Management Inc.

Eqis Capital Management Inc. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 20.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,270 shares of the medical research company’s stock after buying an additional 2,099 shares during the quarter. Eqis Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $3,359,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kentucky Retirement Systems bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $3,322,000. Neuberger Berman Group LLC raised its holdings in shares of Thermo Fisher Scientific by 35.6% in the 3rd quarter. Neuberger Berman Group LLC now owns 210,762 shares of the medical research company’s stock valued at $51,443,000 after purchasing an additional 55,336 shares in the last quarter. B. Riley Wealth Management Inc. bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $2,468,000. Lombard Odier Asset Management USA Corp bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $2,441,000. Finally, Legal & General Group Plc raised its holdings in shares of Thermo Fisher Scientific by 4.0% in the 3rd quarter. Legal & General Group Plc now owns 1,847,206 shares of the medical research company’s stock valued at $450,856,000 after purchasing an additional 70,872 shares in the last quarter. Institutional investors own 88.66% of the company’s stock.

Several equities research analysts have recently commented on TMO shares. Bank of America restated a “buy” rating and issued a $300.00 price target (up previously from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. BTIG Research boosted their price target on shares of Thermo Fisher Scientific to $290.00 and gave the company a “buy” rating in a report on Thursday, January 31st. Barclays boosted their price target on shares of Thermo Fisher Scientific from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, January 3rd. UBS Group boosted their price target on shares of Thermo Fisher Scientific to $305.00 and gave the company a “buy” rating in a report on Monday, March 25th. Finally, Needham & Company LLC started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $271.00 price target for the company. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $289.92.

In related news, CAO Peter E. Hornstra sold 5,920 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $250.00, for a total transaction of $1,480,000.00. Following the completion of the transaction, the chief accounting officer now owns 17,057 shares in the company, valued at approximately $4,264,250. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Gregory J. Herrema sold 5,400 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $251.51, for a total transaction of $1,358,154.00. Following the sale, the senior vice president now directly owns 31,846 shares in the company, valued at approximately $8,009,587.46. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,927 shares of company stock valued at $9,388,124. 0.49% of the stock is currently owned by company insiders.

NYSE TMO opened at $259.78 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.73 and a quick ratio of 1.24. The company has a market cap of $103.65 billion, a P/E ratio of 23.36, a PEG ratio of 1.83 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 52 week low of $202.83 and a 52 week high of $282.98.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping the consensus estimate of $3.19 by $0.06. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.79 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 12.15 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 16th. Investors of record on Friday, March 15th were paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s payout ratio is 6.83%.

ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific Inc. (TMO) Shares Bought by Eqis Capital Management Inc.” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/thermo-fisher-scientific-inc-tmo-shares-bought-by-eqis-capital-management-inc.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: Buyback For Investors Defined

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.